Advertisement
Advertisement

Once-Daily Option for Pediatric Use of Prezista

March/April 2013

On 1 February 2013, the FDA approved revisions to the darunavir (Prezista) tablet and oral suspension label to include paediatric use.

This included once daily dosing in treatment-naive subjects 3 to less than 18 years of age and once-daily dosing in treatment-experienced subjects 3 to less than 18 years of age with no darunavir resistance associated substitutions.

Weight-based dosing tables are included by age, weight and treatment experience.

For full details please see the full label and/or online infromation from the FDA list serve.

Source: FDA list serve. Prezista (darunavir) tablet and oral suspension: pediatric dosing. (1 February 2013).

Links to other websites are current at date of posting but not maintained.




Visit HIV i-Base's website to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.